Author Archives: Vijaya Iyer, PhD

International Biophysics, the maker of AffloVest, announced that it is continuing to support people with cystic fibrosis and efforts to raise awareness about this disease, donating 50 of its airway clearance therapy vests to be distributed across the U.S. AffloVests are being given away, one in each state,…

The Cystic Fibrosis Foundation (CFF) recognized CARSTAR — the largest franchise network of auto body repair service in North America — as one of its National Corporate Champions of the year for raising more than $100,000 toward cystic fibrosis (CF) research and care. CARSTAR also received the Rising Star…

Synspira Therapeutics’s candidate for treating cystic fibrosis, SNSP113, has received orphan drug designation from the European Medicines’ Agency (EMA) in the European Union. The status was granted by the EMA’s Committee for Orphan Medicinal Products (COMP), which reviews experimental treatments developed for rare diseases. Thick mucus accumulates…

Blocking the enzyme cathepsin S can alleviate symptoms and reduce lung damage in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), according to multinational teams led by researchers at Queen’s University Belfast, U.K. The findings on CF were reported in the study “Targeting of Cathepsin…

ContraFect will receive up to $6.94 million in funding from CARB-X to support the development of their proprietary therapeutic peptides — amurins — against antibiotic-resistant bacterial infections caused by gram-negative ESKAPE pathogens. The company intends to develop these compounds as potential therapies for pulmonary exacerbations of cystic fibrosis and hospital-acquired…

MaRS Innovation recently announced the launch of two new projects targeting the development of new therapeutics for cystic fibrosis (CF) and respiratory syncytial virus (RSV). These projects are part of LAB150, MaRS Innovation’s joint venture with Evotec AG to support collaboration among scientists, investors, and pharmaceutical companies to…

NetNoggin has launched a new cystic fibrosis (CF) market research report to highlight patient and caregiver experiences and their perspectives about the gaps in CF research, the company announced. NetNoggin is a company that specializes in pharmaceutical marketing. The new offering, called NetNog: #genesis Cystic Fibrosis Patient and Caregiver…

Emily’s Hope and Cisco have raised more than $1 million as part of Great Strides – a Cystic Fibrosis Foundation (CFF) fundraiser – becoming its top-performing national corporate team for the event. The Great Strides walk event is CFF’s largest national fundraiser that seeks to raise awareness about cystic…

Enrollment for a Phase 3 clinical trial testing AeroVanc in patients with cystic fibrosis with methicillin-resistant Staphylococcus aureus (MRSA) lung infections is expected to be completed in the third quarter of this year — between July and September. AeroVanc is an inhaled formulation of the antibiotic vancomycin hydrochloride being developed…

A reassessment of U.K. medical records showed that in cystic fibrosis (CF) patients, breathing support provided by gas inhalation, through a face or nasal mask, helps improve lung function but not survival, researchers report. The study “Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from…